June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Focal OCT defects are predictors for future glaucoma progression in the same region
Author Affiliations & Notes
  • Ari Leshno
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Xin Xin Xing
    Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States
  • Emmanouil (Manos) Tsamis
    Columbia University, New York, New York, United States
  • Gabriel Gomide
    Columbia University, New York, New York, United States
  • Sol La Bruna
    Columbia University, New York, New York, United States
  • C. Gustavo De Moraes
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • George A Cioffi
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Sitara Hanif Hirji
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Donald C Hood
    Columbia University, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Ari Leshno Schur Family Glaucoma Fellowship, Columbia University Department of Ophthalmology., Code F (Financial Support); Xin Xin Xing None; Emmanouil (Manos) Tsamis None; Gabriel Gomide None; Sol La Bruna None; C. Gustavo De Moraes Carl Zeiss, Novartis, PerfuseTheraputics, Thea Pharma, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment); George Cioffi None; Sitara Hirji None; Donald Hood Novartis, Topcon, Inc., Heidelberg Engineering Inc.,, Code F (Financial Support), Topcon Inc., Heidelberg Engineering, Inc., Code R (Recipient); Jeffrey Liebmann AdvanceSight, Alcon, Inc., Allergan, Inc., Carl Zeiss Meditech, Genentech, Inc., Johnson & Johnson, Inc., ONL Therapeutics, Inc., Thea, Inc., Code C (Consultant/Contractor)
  • Footnotes
    Support  Schur Family Glaucoma Fellowship, Columbia University Department of Ophthalmology
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2023. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ari Leshno, Xin Xin Xing, Emmanouil (Manos) Tsamis, Gabriel Gomide, Sol La Bruna, C. Gustavo De Moraes, George A Cioffi, Sitara Hanif Hirji, Donald C Hood, Jeffrey M Liebmann; Focal OCT defects are predictors for future glaucoma progression in the same region. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2023.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To test the hypothesis that the presence of focal glaucomatous structural defects (i.e., a defect only in one hemi-retina) predicts further progression in the same region.

Methods : We created a database of all Humphrey visual field tests (VF) and Cirrus optical coherence tomography (OCT) scans of the disc and macular (Carl Zeiss) from glaucoma patients seen between 02/01/2020 and 05/10/2022. Overall, 78,298 VF and 49,559 OCT scans from 11,234 eyes (6,495 patients) were collected. We included only those eyes with same-day 24-2 VF and OCT exams on at least five visits, a minimum of 5 years follow-up, and a superior OR inferior glaucomatous structural defect, as defined by the Columbia University OCT-based method (CU-method) of RNFL defect with corresponding ganglion cell layer (GCL) loss.1,2 Progression was defined as a hemi-retinal RNFL rate of change (ROC) worse than -1 µm/year and a corresponding GCL ROC worse than -0.5 µm/year using the commercially available Forum Structure-Function guided progression analysis (GPA, Carl Zeiss).3

Results : 98 eyes (83 patients, follow-up duration [Median, range]: 6.7, 5.1-11.3 years; visits: 5.5, 5-14) had inferior (n=66) OR superior (n=32) RNFL and commensurate GCL defects (Fig. 1). A total of 57 eyes (58%) progressed. 50/57 (87.7%) progressed in the same hemiretina as the original defect. 33/57 (57.9%) developed a defect in the opposite, previously normal, hemiretina. 26 of these 33 eyes (78.8%), also had structural progression in the same hemiretina as the original defect (P=0.004). The probability of developing a new defect was not significantly different based on whether the original defect was in the superior or inferior hemiretina (P = 0.142).

Conclusions : Glaucomatous structural damage is more likely to progress within an already damaged region than in a previously healthy region. In eyes with an existing structural defect, a new structural defect is typically accompanied by progression of the initial defect. An isolated OCT defect is a surrogate for future glaucoma progression in the same region.
References: Liebmann et al, JOG 2022; 2. Hood et al. PRER, 2022; 3. Hammel et al AJO 2017

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×